Internship

Intern – Supply Chain & Technical Operations

Updated on 12/5/2024

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function improvement

Biotechnology
Healthcare

Villanova, PA, USA + 1 more

More locations: San Bruno, CA, USA

Internship at South San Francisco headquarters for approximately 12 weeks.

Category
Supply Chain Management
Operations & Logistics
Required Skills
Supply Chain Management
Inventory Management
Requirements
  • We are looking for candidates who are pursuing a career in Supply Chain Management, Operations Management, or any of the following key sciences: Biology, Chemistry, or Engineering
  • Previous Supply Chain intern or work experience is a plus, but not required
Responsibilities
  • Learn and expand knowledge of Global Supply Chain design, strategy and integration of critical activities with product Development and Technical Operations
  • Engage in supply chain design, inventory management, supply planning and business process design; this is a hands-on role supporting the launch preparations for Aficamten in 2025
  • Analyze global supply chain design and establish clear launch plan activities for global product

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma for R&D and commercial launches.
  • Positive Phase III results for aficamten in treating obstructive hypertrophic cardiomyopathy.
  • FDA initiatives may expedite approval for Cytokinetics' rare disease treatments.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos in hypertrophic cardiomyopathy market.
  • Dependence on successful clinical trials like SEQUOIA-HCM for financial stability.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets rare conditions like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics has a robust pipeline, including drugs like omecamtiv mecarbil and aficamten.

Help us improve and share your feedback! Did you find this helpful?